Vaxcyte reports positive Phase 3 results for experimental pneumococcal vaccine
🤖 AI-generated content — The title and summary were produced automatically by artificial intelligence, without human editorial review.
Vaxcyte announced on Monday that its VAX-31 pneumococcal vaccine met primary endpoints in a Phase 3 clinical trial involving just over 3,500 adults aged 50 and older. The vaccine covers 31 bacterial strains, positioning the California-based biotech to compete with Pfizer's 20-strain Prevnar and Merck's 21-strain Capvaxive.
Continue in the app — vote & join in ➔Source: STAT News · via ahirlevel.hu